Alessandro Di Sanzo

Articles by Alessandro Di Sanzo

TIP134 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From ER+/HER2– Breast Cancer

ByNuhad Ibrahim, MD,Eva Ciruelos Gil,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Tomer Wasserman,Erika P. Hamilton, MD

May 4th 2026

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

23 ELECTRA: An Open-Label, Multicenter, Phase 1b/2 Study of Elacestrant in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2-Negative (HER2) Breast Cancer (BC)

ByNuhad Ibrahim, MD,Sung-Bae Kim,Nancy U. Lin, MD,Ahmad Awada,Eva Ciruelos Gil,Alessandro Di Sanzo,Bartomeu Piza Vallespir,Kathy Puyana Theall,Erika P. Hamilton, MD

August 3rd 2024

Latest Updated Articles

Trending on CancerNetwork

Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC

Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC

PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer

Cesalatamig Monotherapy Yields Responses in PD-(L)1–Resistant NSCLC

Managing Dermatologic Toxicity and Holding Therapy